Tuheen Huda1, Peter D G Alexander2, Brendan A McGrath3, Cliff S Shelton4. 1. Specialist Trainee in Intensive Care Medicine, Manchester University Hospital NHS Foundation Trust, Southmoor Road, Wythenshawe M23 9LT, UK. Electronic address: tuheen.huda@mft.nhs.uk. 2. Consultant in Anaesthesia and Intensive Care Medicine, Wythenshawe Hospital, Manchester University Hospital NHS Foundation Trust, Southmoor Road, Wythenshawe M23 9LT, UK. 3. Honorary Senior Lecturer, Manchester Academic Critical Care, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, the University of Manchster, Manchester Academic Health Centre, Oxford Road, Manchester M13 9PL, UK. 4. Senior Clinical Lecturer in Anaesthesia, Lancaster Medical School, Faculty of Health and Medicine, Lancaster University Lancaster, UK.
Dear Editor,We read with interest the report by Filho and colleagues describing their prototype barrier device for open tracheostomy during the COVID-19 pandemic Auris Nasus Larynx. 2020 May 8. pii: S0385-8146(20)30119-X [1]. We agree that not all countries or institutions have access to what might be considered the optimal environment and equipment to safely undertake tracheostomy in patients recovering from COVID-19, but we have some concerns about promoting a barrier device to address these needs. These concerns are based on our own experiences of simulated airway management behind barrier enclosures, and from other reports in the literature [2,3].Elective tracheostomy should be approached with the same principles as any airway procedure [4], except that patients with COVID-19 may present additional infective risks to the operating theatre team [5]. Whilst the development of novel solutions to mitigate aerosol generation or spread of virus should be encouraged, we do not advocate the adoption of unproven technologies or techniques into clinical practice without detailed validation. These concerns have been reported in the anesthesiology literature [2,3], with key unanswered questions concerning barrier-type devices, including:What is the distribution of aerosolised particles once the box is removed?Does putting ones’ hands and arms in and out of the barrier device damage or disrupt the integrity of the personal protective equipment (PPE) worn by the operator?Does the presence of a barrier increase time to complete the procedure or influence the rate of first‐pass success?How are additional pieces of equipment or different tracheal tubes brought into the barrier device without contaminating the equipment or the environment?The authors suggest leaving the barrier in place for a (pragmatic) 3-hour period after the tracheostomy has been performed to allow aerosols to dissipate. However, problems can arise with new tracheostomies which require prompt recognition and timely management [6]. This, along with the unanswered questions outlined above, may be further compounded by time pressures; impairment of vision and dexterity due to PPE and the barrier itself; and a critically ill patient who is at risk of hypoxemia. We therefore suggest that clinicians address the potential limitations of the technique as described, so that the added layer of complexity, to an already complex procedure can be navigated to the benefit of clinicians adopting this practice.We found it a pleasure to read this report and admired the ingenuity of our clinical colleagues, despite our multiple concerns with its implementation. The challenges to safety conscious practice come in many forms, and we thank Filho et. al for their thought provoking article.
Authors: Brendan A McGrath; Michael J Brenner; Stephen J Warrillow; Vinciya Pandian; Asit Arora; Tanis S Cameron; José Manuel Añon; Gonzalo Hernández Martínez; Robert D Truog; Susan D Block; Grace C Y Lui; Christine McDonald; Christopher H Rassekh; Joshua Atkins; Li Qiang; Sébastien Vergez; Pavel Dulguerov; Johannes Zenk; Massimo Antonelli; Paolo Pelosi; Brian K Walsh; Erin Ward; You Shang; Stefano Gasparini; Abele Donati; Mervyn Singer; Peter J M Openshaw; Neil Tolley; Howard Markel; David J Feller-Kopman Journal: Lancet Respir Med Date: 2020-05-15 Impact factor: 30.700
Authors: Carla L Gould; Peter D G Alexander; Claire N Allen; Brendan A McGrath; Clifford L Shelton Journal: Br J Anaesth Date: 2020-05-13 Impact factor: 9.166